Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research report report published on Friday.

Several other analysts have also recently commented on MCRB. Chardan Capital reiterated a “neutral” rating and issued a $6.00 price target (up previously from $1.25) on shares of Seres Therapeutics in a research note on Thursday. The Goldman Sachs Group decreased their price target on shares of Seres Therapeutics from $20.00 to $15.00 and set a “sell” rating on the stock in a research note on Friday, March 14th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $73.67.

Seres Therapeutics Stock Performance

MCRB opened at $7.05 on Friday. Seres Therapeutics has a fifty-two week low of $6.64 and a fifty-two week high of $30.60. The firm’s fifty day moving average is $11.67 and its 200 day moving average is $14.66. The stock has a market cap of $61.46 million, a price-to-earnings ratio of -30.65 and a beta of 2.89.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($1.57). On average, equities research analysts predict that Seres Therapeutics will post -0.38 earnings per share for the current year.

Institutional Trading of Seres Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. increased its holdings in shares of Seres Therapeutics by 137.6% in the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock worth $780,000 after buying an additional 543,469 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Seres Therapeutics by 15.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock worth $720,000 after buying an additional 117,107 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Seres Therapeutics by 22.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after buying an additional 255,014 shares during the last quarter. Avantax Advisory Services Inc. increased its holdings in shares of Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after buying an additional 28,500 shares during the last quarter. Finally, Virtu Financial LLC increased its holdings in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after buying an additional 18,191 shares during the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.